Performance evaluation of a newly developed 2019-nCoV nucleic acid detection kit based on Ion Proton sequencing platform and its comparison with the MGI Tech (DNBSEQ-G99) platform.

Publication date: Jul 01, 2024

To evaluate the performance of a newly developed 2019-nCoV nucleic acid detection kit based on Ion Proton sequencing platform and make comparation with MGI Tech (DNBSEQ-G99) platform. References and clinical samples were used to evaluate the precision, agreement rate, limit of detection (LOD), anti-interference ability and analytical specificity. Twenty-seven clinical specimens were used to make comparison between two platforms. The kit showed good intra-assay, inter-assay, inter-day precision between different operators and laboratories, fine agreement rate with references, a relatively low LOD of 1 cD7 10 copies/ml, anti-interference capability of 5 % whole blood and 1mg/ml mucin and no cross reaction with twenty-nine common clinical pathogens. Consistency of variant classification was observed between two platforms. The WGS from Ion Proton tended to have higher coverage and less missing data. The newly developed kit has shown satisfactory performances and excellent consistency with DNBSEQ-G99, making it a good alternative choice clinically.

Concepts Keywords
G99 COVID-19
Pathogens High-Throughput Nucleotide Sequencing
Performances Humans
Proton Ion Proton
Limit of Detection
MGI Tech (DNBSEQ-G99)
Next-generation sequencing
Performance evaluation
Reagent Kits, Diagnostic
Reagent Kits, Diagnostic
RNA, Viral
RNA, Viral
SARS-CoV-2
Sensitivity and Specificity

Semantics

Type Source Name
disease IDO assay
disease MESH COVID-19

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *